{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 99 of 129', 'applicable, and analysed according to the primary analysis of the primary estimand for the', 'continuous secondary endpoints. For the Eczema-related Sleep NRS score, the mean over the', 'last 7 days prior to randomisation (Day -6 to 0) will be used as the baseline value.', 'For the PGI-B, a day of \"no or slight bother\\' is defined as answering the question with \"not at', 'all\" or \"slightly\". The subjects\\' number of days of \\'no or slight bother\\' will be tabulated per', 'treatment group for the initial treatment period. The mean number of days will be presented', 'with 95% CIs and compared between the 2 treatment groups using an analysis of variance', 'model including treatment, region, and baseline IGA as factors.', '12.3.9 Analysis of safety', 'The analyses of safety will be based on the safety analysis set. The reporting of safety data', 'will be presented separately for initial treatment and continuation treatment.', '12.3.9.1 Adverse events', 'To assess the safety of tralokinumab in combination with TCS when used to treat moderate-', 'to-severe AD for 32 weeks, the frequency of AEs and SAEs are included as additional', 'secondary endpoints.', 'AEs will be coded during the course of the trial according to Medical Dictionary for', 'Regulatory Activities (MedDRA). AEs will be presented by preferred terms and primary', 'system organ class (SOC).', 'Treatment-emergent AEs will be summarised, however, all AEs recorded during the course of', 'the trial will be included in the subject data listings. An event will be considered', 'treatment-emergent if started after the first use of IMP or if started before the first use of IMP', '(applicable if subject had a wash-out) and worsened in severity thereafter. The tabulations', 'described in the following will only include the treatment-emergent events. In each of the', 'tabulations, AEs will be defined by MedDRA preferred terms within primary SOC.', 'An overall summary of the number of treatment-emergent AEs and the number (percentage)', 'of subjects with any treatment-emergent AEs, deaths, SAEs, premature discontinuations from', 'the trial due to AEs, treatment-related AEs and severe AEs will be presented.', 'The number of AEs and the number of subjects experiencing each type of AE will be', 'tabulated by treatment group. The percentage of subjects with AEs in the initial treatment', \"period will be compared between treatment groups by a chi-square test or Fisher's exact test\", '(if expected cell count <5).', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 100 of 129', 'The severity for each type of AE will be tabulated by treatment group.', 'The causal relationship to IMP and NIMP (TCS) for each type of AE will be tabulated by', 'treatment group.', 'Related AEs are defined as AEs for which the investigator has not described the causal', 'relationship to IMP as \"not related\\'. The number of related AEs and the number of subjects', 'experiencing each type of related AE will be tabulated. The percentage of subjects with', 'related AEs in the initial treatment period will be compared between treatment groups by a', \"chi-square test or Fisher's exact test (if expected cell count <5).\", 'SAEs and AESIs will be evaluated separately. A narrative for each SAE will be given. AESIs', 'and AEs leading to withdrawal from trial or permanent discontinuation of IMP will be', 'tabulated and listed.', '12.3.9.2 Vital signs', 'The change in vital signs (blood pressure, heart rate, body temperature) from baseline to each', 'visit will be summarised by visit and treatment group as mean, standard deviation, median,', 'minimum and maximum values for the safety analysis set and the continuation treatment', 'safety analysis set.', '12.3.9.3 Clinical laboratory evaluation', 'The change in each of the laboratory parameters from baseline to each visit will be', 'summarised by visit and treatment group as mean, standard deviation, median, minimum and', 'maximum values for the safety analysis set and the continuation treatment safety analysis set.', 'Laboratory parameters will be classified as \\'low\\', \\'normal\\' or \"high\\', depending on whether', 'the value is below, within or above the reference range, respectively. A shift table will be', 'produced showing the categories at baseline against those at end of treatment. Subjects with', 'laboratory parameters outside the reference range will be listed.', '12.3.9.4 Pharmacokinetics', 'All the PK samples in the trial are trough samples. The trough concentration (Ctrough) will be', 'listed by treatment group and descriptive statistics will be applied.', 'Ctrough values from subjects with positive ADA/nAB will be compared to values from subjects', 'with negative ADA/nAB if data permits.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}